Capivasertib/Fulvestrant Boosts Progression-Free Survival in HR+/HER2– Breast Cancer
Capivasertib plus fulvestrant improved progression-free survival in patients who have hormone-receptor–positive/HER2-negative advanced breast cancer.
DRd Outperforms Rd in Newly Diagnosed Multiple Myeloma
Daratumumab plus lenalidomide and dexamethasone bested standard therapy in producing rapid, deep, and durable responses across subgroups of patients with newly diagnosed multiple myeloma.
Carolina Frailty Index Score May Be Applicable in Assessment of Patients with Ovarian Cancer
GCLQ and LELSQ Show Concordance in Assessment of Lymphedema in Patients With Endometrial Cancer
Pollack Discusses Ongoing Research for Patients With Refractory mCRC and Other Hard-to-Treat GI Malignancies
Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium
2 Clarke Drive Cranbury, NJ 08512